000			01493 a2200445 4500
005			20250512103941.0
264		0	_c19690108
008			196901s 0 0 eng d
022			_a0098-7484
024	7		_a10.1001/jama.206.12.2698 _2doi
040			_aNLM _beng _cNLM
100	1		_aJohnson, W D
245	0	0	_aCephaloglycin. Clinical and laboratory experience with an orally administered cephalosporin. _h[electronic resource]
260			_bJAMA _cDec 1968
300			_a2698-702 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAnti-Bacterial Agents _xadministration & dosage
650	0	4	_aCephalosporins _xadministration & dosage
650	0	4	_aChild
650	0	4	_aDrug Resistance, Microbial
650	0	4	_aEnterobacter _xdrug effects
650	0	4	_aEscherichia coli _xdrug effects
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aKlebsiella _xdrug effects
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aProteus _xdrug effects
650	0	4	_aPseudomonas aeruginosa _xdrug effects
650	0	4	_aStaphylococcus _xdrug effects
650	0	4	_aStreptococcus pneumoniae _xdrug effects
650	0	4	_aUrinary Tract Infections _xdrug therapy
700	1		_aApplestein, J M
700	1		_aKaye, D
773	0		_tJAMA _gvol. 206 _gno. 12 _gp. 2698-702
856	4	0	_uhttps://doi.org/10.1001/jama.206.12.2698 _zAvailable from publisher's website
999			_c4391655 _d4391655